地诺单抗的适应症

Indications: Denosumab is approved for the treatment of breast cancer and is also approved for the prevention of bone-related events in solid tumors with bone metastasis, but not for the prevention of bone-related events in multiple myeloma. It is approved for use in adults or bone-mature adolescents with giant bone tumors that are unresectable or may cause severe complications after surgical resection. Approved for hypercalcemia in bisphosphonate-resistant malignancies.

Denosumab is the first approved monoclonal antibody that specifically targets RANK ligand. It specifically targets the receptor activator of NF-kB ligand (RANKL), inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Osteoclasts are responsible for bone resorption, and osteoclast precursors must have low levels of macrophage colony-stimulating factor and RANKL during their differentiation into mature osteoclasts. This product has a high affinity with RANKL, preventing RANK ligand from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis.

Medical Companion Travel would like to tell you that some side effects and complications that may occur during medication may cause harm, and special groups of people need to pay attention when using (Xgeva). In nursing mothers, mammary gland development and lactation may be impaired. Stop or breastfeed. Ultimately, as the safety and effectiveness for children have not been determined, we do not recommend their use. Finally, we should pay special attention to the medication for kidney damage, and it is best to communicate with the doctor in advance.